

1 **Vector control for malaria prevention during humanitarian emergencies: protocol for a**  
2 **systematic review and meta-analysis**

3  
4 Louisa A. Messenger<sup>1</sup>, Joanna Furnival-Adams<sup>1</sup>, Bethanie Pelloquin<sup>1</sup>, Mark Rowland<sup>1</sup>

5  
6 <sup>1</sup> Department of Disease Control, Faculty of Infectious Tropical Diseases, London School of  
7 Hygiene and Tropical Medicine, London, United Kingdom

8  
9 Contact address: Louisa A. Messenger, Department of Disease Control, Faculty of Infectious  
10 Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United  
11 Kingdom.

12 [Louisa.messenger@lshtm.ac.uk](mailto:Louisa.messenger@lshtm.ac.uk)  
13

14 **Abstract (300 words)**

15 **Introduction** Humanitarian emergencies, of either natural or anthropogenic origins, are  
16 equivalent to major disasters, which can lead to population displacement, food insecurity  
17 and health system disruptions. Almost two-thirds of persons affected by humanitarian  
18 emergencies inhabit malaria endemic regions, particularly the World Health Organization  
19 (WHO) African Region, which currently accounts for 93% and 94% of malaria cases and  
20 deaths, respectively. As of late 2020, the United Nations Refugee Agency estimates there  
21 are globally 79.5 million forcibly displaced people, including 45.7 million internally displaced  
22 people, 26 million refugees, 4.2 million asylum-seekers and 3.6 million Venezuelans  
23 displaced abroad.

24 **Methods and analyses** A systematic review and meta-analysis will be conducted to  
25 evaluate the impact of different vector control interventions on malaria disease burden  
26 during humanitarian emergencies. Published and grey literature will be systematically  
27 retrieved from ten electronic databases and three clinical trials registries. A systematic  
28 approach to screening, reviewing and data extraction will be applied based on the Preferred  
29 Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Two  
30 review authors will independently assess full-text copies of potentially relevant articles based  
31 on inclusion criteria. Included studies will be assessed for risk of bias according to Cochrane  
32 and certainty of evidence using the GRADE approach. Eligible studies with reported or  
33 measurable risk ratios or odds ratios with 95% confidence intervals will be included in a  
34 meta-analysis. Sub-group analyses, including per study design, emergency phase, and  
35 primary mode of intervention, may be performed if substantial heterogeneity is encountered.

36 **Ethics and dissemination** Ethical approval is not required by the London School of  
37 Hygiene and Tropical Medicine to perform secondary analyses of existing anonymous data.  
38 Study findings will be disseminated via open-access publications in peer-reviewed journals,  
39 presentations to stakeholders and international policy makers, and will contribute to the  
40 latest WHO guidelines for malaria control during humanitarian emergencies.  
41

42 **PROSPERO registration number** CRD42020214961.  
43  
44  
45  
46

## 47 Strengths and limitations of this study

- 48 ⇒ This will be the first systematic review and meta-analysis of the impact of different  
49 vector control interventions on malaria disease burden during humanitarian  
50 emergencies, providing a comprehensive global evidence summary that can be  
51 updated as new evidence emerges.
- 52 ⇒ Inclusion of a broad range of study types will allow the identification of studies from a  
53 diverse range of humanitarian contexts.
- 54 ⇒ By definition, humanitarian emergencies are unpredictable and volatile and  
55 consequently these settings can be restrictive with respect to study design, limiting  
56 the number of community-level randomised control trials with epidemiological  
57 outcomes which can be considered in this review.
- 58 ⇒ Lack of a sensitive literature search strategy may result in a large number of titles  
59 and abstracts to screen initially.

60

## 61 INTRODUCTION

### 62 *Malaria in humanitarian emergencies*

63

64 Malaria is a life-threatening parasitic disease caused by *Plasmodium* species and  
65 transmitted by female *Anopheles* mosquitoes.<sup>1</sup> In 2018, there were an estimated 228 million  
66 cases of malaria worldwide, including 405,000 deaths.<sup>1</sup> As defined by the WHO, a  
67 humanitarian emergency is a calamitous situation in which the functioning of a community or  
68 society is severely disrupted, causing human suffering and material loss that exceeds the  
69 affected population's ability to cope using its own resources.<sup>3</sup> Both natural (e.g. earthquakes,  
70 floods or tsunamis) and anthropogenic (e.g. violent political conflicts) hazards can lead to  
71 humanitarian emergencies, which may involve population displacement, food insecurity and  
72 disruptions to health systems; all of these factors contribute to excess mortality and  
73 morbidity among affected communities. While natural disasters may be short-lived, complex  
74 emergencies are often protracted, characterized by having complex social, political and  
75 economic origins, breakdown of governmental authority and infrastructures and often armed  
76 political conflict and human rights abuses.<sup>3</sup> Globally, the United Nations Refugee Agency  
77 (UNHCR) currently estimates there are 79.5 million forcibly displaced people<sup>4</sup>; with almost  
78 two-thirds of persons affected by humanitarian emergencies inhabiting malaria endemic  
79 regions.<sup>2</sup> (Figure 1).

80

81

82 **Figure 1. Left:** Global map of internally displaced people (green) and refugee (red)  
83 populations, 2020. The UNHCR currently estimates there are 79.5 million forcibly displaced  
84 people, including 45.7 million internally displaced people, 26 million refugees, 4.2 million  
85 asylum-seekers and 3.6 million Venezuelans displaced abroad.<sup>4</sup> **Right:** Global map of  
86 *Plasmodium falciparum* parasite rate in children aged 2-10 years old, 2000-2017.<sup>5</sup>

87

88 Mass population displacement can increase the risk of epidemics and incidence of severe  
89 malaria, especially when immunologically-naive individuals with little to no prior malaria  
90 exposure move to areas of more intense transmission. These populations are rendered  
91 vulnerable to epidemic malaria by their lack of protective immunity, increased concentration  
92 of people in exposed settings, inadequate health services, breakdown of national malaria  
93 control programmes, loss or emigration of skilled healthcare workers, insufficient access to  
94 effective treatment and control measures, food scarcity, and concomitant infections,  
95 malnutrition and anaemia.<sup>3</sup> During humanitarian emergencies, malaria morbidity and

96 mortality can contribute to the breakdown of health services and local case management,  
97 which can both worsen and be a source of the emergency.

98  
99

#### 100 *Humanitarian emergency features and settings*

101

102 Humanitarian emergencies can be classified by their speed of onset, duration and setting,  
103 which all have implications for infectious disease control strategies (Figure 2). Rapid- and  
104 slow-onset emergencies describe a sudden or gradual deteriorating situation, respectively,  
105 while protracted (chronic) emergencies involve consistently high levels of humanitarian  
106 need. The criteria of the acute phase (Phase 1 and 2 in Figure 2), are elevated mortality  
107 rates, poor access to effective healthcare for the affected population, response needs that  
108 are beyond local or national capacity, and possible breakdown of normal coordination and  
109 response mechanisms. The post-acute phase (Phase 3), includes a reduction in peak  
110 mortality rates and improved access to humanitarian aid and healthcare. The recovery  
111 phase (Phase 4), is characterised by resumption of government, the withdrawal of  
112 humanitarian agencies, and introduction of development UN and NGO programmes and  
113 agencies. However, returning refugees may also re-integrate, bringing malaria with them,  
114 and depending on the level of strategic interest this phase may or may not be neglected  
115 internationally. Protracted emergencies can remain entrenched in the post-acute/early-  
116 recovery phases or cycle between acute and post-acute phases indefinitely.

117

118

119 **Figure 2.** Phases of sudden-onset, slow-onset or protracted (chronic) humanitarian  
120 emergencies. Time is indicated in days (D), weeks (W) and months (M). Adapted from <sup>3</sup>.

121

122

#### 123 *Malaria vector control during humanitarian emergencies*

124

125 During the acute phase of a humanitarian emergency, the first priorities for malaria control  
126 are effective case management, with prompt diagnosis and treatment.<sup>3</sup> Choice of vector  
127 control intervention will be determined by a number of key factors including, malaria infection  
128 risk and transmission dynamics, population demographics, prior malaria exposure,  
129 behaviour and mobility, vector species composition, vector feeding and resting preferences  
130 and emergency settings and infrastructure (Table 1).

131

132 WHO recommended malaria control interventions, insecticide-treated nets (ITNs) and indoor  
133 residual spraying (IRS), are the first line preventative measures considered. Effective case  
134 management can be supplemented with long-lasting insecticidal net (LLIN) distributions, first  
135 targeting the most vulnerable populations (e.g. pregnant women and children under-5 years  
136 old), with the goal of achieving and maintaining universal community-level coverage.<sup>6-8</sup> IRS  
137 can be applied in well-organised, politically-stable settings, such as transit camps, but is  
138 generally not feasible when dwellings are scattered widely, of a temporary nature, or  
139 constructed with surfaces that are unsuitable for spraying.<sup>9</sup> IRS is more appropriate for  
140 protecting larger refugee populations in more compact and stable settings where housing is  
141 more permanent and structurally sound, and there is an absence of alternative resting  
142 sites.<sup>10</sup> Targeted IRS can also supplement LLINs and be used together for insecticide  
143 resistance management.<sup>11 12</sup>

144

145 A suite of other community-level and personal vector control interventions has been  
146 designed for deployment during humanitarian emergencies, which will be considered in this  
147 review. One strategy has been to exploit utilitarian shelter materials, often provided in the  
148 early stages of emergencies, such as plastic sheeting, tarpaulins and tents, as mechanisms  
149 of insecticide delivery.<sup>13-16</sup> Additional opportunities identified to apply insecticide among at-  
risk populations have included distributing insecticide treated bed sheets and blankets,

150 clothing, hammocks and wall lining,<sup>17-25</sup> and use of topical insecticides for human populations  
151 <sup>26 27</sup> or to treat community livestock.<sup>28</sup>

152 Most interventions act by delivering a lethal dose of insecticide to the adult mosquito,  
153 protecting the host from exposure to a potentially infective bite. Some of these interventions,  
154 notably LLINs and IRS, may also have a community wide benefit (in areas of vector  
155 susceptibility to the active ingredients), decreasing mosquito density and longevity, and  
156 ultimately interrupting malaria transmission. The insecticide used is dependent on the  
157 intervention and resistance profiles of local vector species.<sup>30 31</sup> Other interventions, such as  
158 topical repellents, work by preventing mosquitoes from detecting the host, by disrupting  
159 olfactory reception.<sup>32</sup> These interventions only provide individual protection and do not  
160 impact vectorial capacity.<sup>30</sup>

161 There are multiple factors involved in ensuring a successful vector control programme during  
162 humanitarian emergencies. The intervention(s) selected must be feasible and consider local  
163 vector species, human resources, funding, logistics and population mobility.<sup>3</sup> Other benefits  
164 of vector control interventions, which may make them more acceptable to the user, include  
165 reducing flies in households and nuisance biting.<sup>33</sup> and improved health and yields of treated  
166 livestock.<sup>28</sup> Some interventions may have low acceptability, for example, sleeping under an  
167 ITN or treated blanket/bedsheet in hot, humid conditions, some types of treated clothing may  
168 be culturally inappropriate, topical repellents may cause irritation to individuals, and there  
169 may be a decrease in adherence over time to interventions which require sustained  
170 behavioural changes.<sup>27</sup>

171

## 172 **Why it is important to do this review**

173 To date, there has been insufficient, systematic syntheses of evidence for the WHO to make  
174 recommendations for deployment of malaria vector control interventions in humanitarian  
175 settings. While a number of aforementioned interventions have either been evaluated during  
176 or developed specifically for use in humanitarian emergencies, the often unpredictable and  
177 volatile nature of these settings can often be restrictive in terms of designing experimental  
178 studies. Given these logistical constraints, a range of both observational and experimental  
179 study designs will be considered.

## 180 **Objectives**

181 This study aims to evaluate the impact of different vector control interventions on malaria  
182 disease burden during humanitarian emergencies.  
183

184 Primary objective is:

- 185 - To evaluate the impact of different vector control interventions on malaria disease  
186 burden during humanitarian emergencies.

187 Secondary objectives are:

188

- 189 - To explore whether the impact of the different vector control interventions varies with  
190 the phase of humanitarian emergency (acute/post-acute, protracted and  
191 recovery/post-conflict phases).
- 192 - To explore whether the impact of the different vector control interventions varies with  
193 the level of malaria transmission (low, <50% parasite rate in children; and high,  
194 >50% parasite rate in children).

- 195 - To explore whether the impact of the different vector control interventions varies with  
196 the level of coverage during a humanitarian emergency.  
197

## 198 **METHODS AND ANALYSES**

199 The following types of studies for inclusion in this review:

- 200
- 201 . Cluster-randomised controlled trials (c-RCTs).
  - 202 . Cluster-randomised cross-over studies.
  - 203 . Cluster-randomised studies using a stepped-wedge design.
  - 204 . Controlled before-and-after studies (CBAs).
  - 205 . Cohort studies (prospective or retrospective).
  - 206 . Non-randomised cross-over studies.
  - 207 . Programmatic evaluations.
  - 208 . Cross-sectional studies.
  - 209 . Case-control studies.
  - 210 . Case series.
  - 211 . Interrupted time series (ITS).
- 212

213 Experimental hut trials, other phase II studies or user acceptability surveys (including,  
214 quantitative knowledge, attitude and practices (KAP) questionnaires or qualitative  
215 observations, in-depth interviews (IDIs) and focus group discussions (FGDs)) will be  
216 summarised descriptively.

217

### 218 **Type of participants**

219

220 Individuals of all age groups affected by humanitarian emergencies in malaria endemic  
221 regions; including those that have been internally displaced by humanitarian emergencies as  
222 well as host communities.

223

### 224 **Type of interventions**

225

226 Any malaria-specific vector control intervention, which has been evaluated during a  
227 humanitarian emergency, will be considered for inclusion (Table 2).

228

### 229 **Type of outcome measures**

230

231 To be eligible for inclusion, studies must report at least one of the following primary  
232 outcomes.

233

### 234 **Primary outcomes**

235

- 236 . Malaria case incidence: measured as number of cases per unit of time or the  
237 number of new uncomplicated malaria cases. We will use site-specific definitions as  
238 long as they have demonstrated (i) a fever or history of fever, and (ii) confirmed  
239 parasitaemia (by blood smear microscopy, rapid diagnostic test (RDT), or  
240 polymerase chain reaction (PCR)).
  - 241 . Malaria infection incidence: measured as count per person per unit of time or the  
242 number of new infections (individuals must have confirmed parasitaemia by blood  
243 smear, RDT or PCR).
  - 244 . Parasite prevalence (clinical and subclinical malaria): the proportion of surveyed  
245 individuals with confirmed parasitaemia at the community-level.
- 246

247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299

## Secondary outcomes

### Epidemiological

- All-case mortality.
- Severe malaria, based on confirmed malaria diagnosis (individuals must have confirmed parasitaemia by blood smear, RDT or PCR) plus the presence of clinical or laboratory features of vital organ dysfunction (these include impaired consciousness, coma, convulsions, respiratory distress, shock (systolic blood pressure <70 mmHg in adults, <50 mmHg in children), jaundice, haemoglobinuria, hypoglycaemia, severe metabolic acidosis and anaemia).
- Anaemia prevalence as per WHO cut-offs, based on haemoglobin measurements taken in community surveys.

### Entomological

- Entomological inoculation rate (EIR): the estimated number of bites by infectious mosquitoes per person per unit of time. This is calculated using the human biting rate (the number of mosquitoes biting an individual over a stated period, measured directly using human baits or indirectly using light traps, knock-down catches, entry or exit traps, baited huts, or other methods of biting rate determination) multiplied by the sporozoite rate.
- Adult mosquito density: measured by a technique previously shown to be appropriate for the particular vector species (e.g. human baits, light-traps, knock-down catches, entry or exit traps, baited huts, or other methods).
- Sporozoite rate: measured as the number of caught adult mosquitoes positive for malaria sporozoites. Sporozoites can be detected through either molecular or immunological methods.

### Operational

- Intervention durability: measured by a technique previously shown to be appropriate, (e.g. a time-series of WHO cone bioassays to monitor IRS residual activity or ITN/LLIN bioefficacy plus HPLC to determine intervention insecticidal content).

### Adverse events

- Any indicators of adverse effects of the intervention, including the following:
  - Reports of toxicity to humans/animals
  - Environmental impacts, such as changes to the biodiversity and ecosystem due to insecticidal use
  - Changes to the levels of phenotypic/molecular insecticide resistance, assessed using standard WHO cylinder assays and/or Centers for Disease Control and Prevention (CDC) bottle bioassays/molecular techniques
  - Changes in mosquito species composition, e.g. species replacement or behaviour that reduces the efficacy of vector control interventions, e.g. an increase in exophily, exophagy, zoophily, or changes in biting time

### Unintended effects

- 300 - Impact on human behaviour, such as changes to individuals' sleeping arrangements  
301 or use of other vector control interventions.  
302 - Other vector-borne disease case incidence (for example, dengue and leishmaniasis).  
303  
304

### 305 **Search methods for identification of studies**

306

307 We will attempt to identify all relevant trials and studies, regardless of language, date or  
308 publication status (published, unpublished, in press and in progress).  
309

### 310 **Electronic searches**

311

312 We will search the following databases: Cochrane Infectious Disease Group Specialized  
313 Register; Central Register of Controlled Trials (CENTRAL), published in the Cochrane  
314 Library; MEDLINE (OvidSP); Africa-Wide Information (EBSCO); the WHO Global Index  
315 Medicus; the Science Citation Index Expanded (Web of Science); the Conference  
316 Proceedings Citation Index – Science (Web of Science); Embase (OvidSP); Global Health  
317 (CABI); and LILACS. We will also search the WHO International Clinical Trials Registry  
318 Platform ([www.who.int/ictrp/search/en](http://www.who.int/ictrp/search/en)), ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)), and the  
319 ISRCTN registry ([www.isrctn.com](http://www.isrctn.com)) to identify ongoing trials.  
320

### 321 **Searching other resources**

322

323 We will contact past and present personnel at key stakeholders, donors, global policy  
324 makers, technical groups, non-governmental organisations (NGOs), manufacturers,  
325 implementers and researchers in the field to identify sources of unpublished data. We will  
326 also check the reference lists of studies identified by the above methods.  
327

### 328 **Data collection and analysis**

329

#### 330 **Selection of studies**

331 Study selection will follow PRISMA guidelines. Two review authors will independently assess  
332 the titles and abstracts of studies identified by the literature searches. These two review  
333 authors will assess full-text copies of potentially relevant articles based on inclusion criteria.  
334 We will compare the results of our assessments and resolve any disagreements by  
335 discussion and consensus, with arbitration by a third review author, if necessary. We will  
336 ensure that multiple publications of the same study are included once. We will list excluded  
337 studies, together with their reasons for exclusion, in a 'Characteristics of excluded studies'  
338 table; any highly relevant studies which did not meet the inclusion criteria, may be included  
339 in a separate annex. The results of the study selection process will be illustrated in a  
340 PRISMA diagram.  
341

#### 342 **Data extraction and management**

343

344 Two review authors will independently extract information from the included studies into a  
345 pre-piloted database, in which study settings, methods and results from identified studies will  
346 be recorded. Disagreements in data extraction will be resolved by discussion and consensus  
347 between the two review authors and arbitration by a third review author, if necessary. In  
348 case of missing data, we will contact the original study author(s) for clarification. Data will be  
349 extracted on the following:

- 350 ● Lead author and publication year.
- 351 ● Study period.

- 352 • Study design: type of study; method of participant selection (for c-RCTs: adjustment  
353 for clustering); cluster size; number of clusters; cross over; sample size.
- 354 • Study participants: population size; origins and length of time in setting (with respect  
355 to the particular emergency situation); characteristics: age, sex, ethnicity, recruitment  
356 rates, withdrawal, loss to follow up, socioeconomic status; levels of prior malaria  
357 exposure; proportion of vulnerable individuals; prevalence of co-morbidities.
- 358 • Humanitarian emergency context: geographic country or area affected; underlying  
359 cause(s) of emergency and relevant mitigating factors; structure and layout of  
360 residence area (e.g. formal camp, informal settlement, open/closed); type of  
361 accommodation or housing available in study area; displacement dynamics and  
362 mobility; road access and condition; details of the political and logistical constraints  
363 encountered during different phases of humanitarian emergencies and their impact  
364 on the feasibility and choice of vector control intervention(s).
- 365 • Epidemiological context: malaria transmission intensity; incidence; prevalence;  
366 *Plasmodium* species.
- 367 • Intervention: description of intervention (active ingredient, dose, formulation,  
368 intervention format, frequency and timing of implementation); coverage, usage and  
369 adherence; any reports of refusals and reasons why.
- 370 • Cointerventions: details of any other malaria or vector-specific control interventions  
371 (such as, mass drug administration, active case detection, health education,  
372 untreated bednets); coverage and adherence; any reports of refusals and reasons  
373 why.
- 374 • Delivery mechanism(s): route of intervention deployment (for example, community-  
375 wide dissemination, health facility-based distributions, integration with other essential  
376 services); any additional information related to the method of implementation,  
377 including who implemented the intervention and who was targeted (the general  
378 population or a sub-population).
- 379 • Outcome measurements: definition of outcome; diagnostic or surveillance method;  
380 passive or active case detection; duration of follow-up; time points at which outcomes  
381 were assessed; number of events; number of participants or unit time; statistical  
382 power; unit of analysis; incomplete outcomes/missing data.
- 383 • Other: primary and secondary vector(s) species; vector(s) behaviour (population  
384 seasonality, adult habitat, peaking biting times, exophilic/endophilic,  
385 exophagic/endophagic, anthropophilic/zoophilic); method of vector collection(s);  
386 baseline measures of phenotypic insecticide resistance and any measures during the  
387 study period; baseline measures of genotypic insecticide resistance and any  
388 measure during the study period; any measure of vector sporozoite rate;  
389 identification of vector bloodmeal(s); vector parity and age structure; any measure of  
390 user acceptability collected during the trial and reported by the treatment arm,  
391 including cross-sectional survey data of reported acceptability and qualitative data on  
392 opinions about the intervention.
- 393 • Identification of major limitations in design, analysis, results, and any aspects that  
394 would limit generalizability of results.
- 395 • Source of funding of the study; reported conflicts of interest of authors.

396  
397  
398 For dichotomous outcomes, we will extract the number of participants experiencing each  
399 outcome and number of participants in each study group. For continuous outcomes, we will  
400 extract number of participants in each study group, the mean and a measure of variance (for  
401 example, standard deviation or standard error). For count/rate data outcomes, we will extract  
402 the number of outcomes in the treatment and control groups, and the total person time at  
403 risk in each group (or the rate ratio), and a measure of variance. For c-RCTs, we will record

404 the number of clusters randomised, number of clusters analysed, measure of effect e.g. risk  
405 ratio, odds ratio or mean difference, with confidence intervals (CIs) or standard deviations,  
406 number of participants and the intra-cluster correlation coefficient (ICC) value. For non-  
407 randomised studies, we will extract adjusted measures of effects that attempt to control for  
408 confounding. If there are no adjusted measures reported, then we will extract unadjusted  
409 measures.

410 Depending on the number of eligible studies per vector control strategy, interventions may  
411 be grouped together and analysed according to their primary mode of action against vector  
412 populations. Studies may be classified as:

- 413 1) Community-wide insecticidal effect, primarily targeting indoor resting vectors, e.g.  
414 IRS, insecticide-treated temporary housing materials and wall linings.
- 415 2) Personal protective insecticidal effect, primarily targeting indoor feeding vectors, e.g.  
416 insecticide-treated bedding material and clothing.
- 417 3) Personal protective insecticidal effect, primarily targeting outdoor feeding vectors,  
418 e.g. personal repellents.
- 419 4) Dual community-wide and personal protective insecticidal effects, primarily targeting  
420 indoor feeding and resting vectors, e.g. ITNs/LLINs and insecticide-treated curtains.
- 421 5) Community-wide insecticidal effect, primarily targeting outdoor resting and feeding  
422 vectors, e.g. insecticide treatment of livestock.
- 423 6) Community-wide insecticidal effect, targeting immature vector stages and potential  
424 breeding sites, e.g. LSM.

425

#### 426 **Assessment of risk of bias in included studies**

427

428 Two review authors will independently assess the risk of bias for each study, consulting a  
429 third review author if necessary. For c-RCTs, we will use the Cochrane 'Risk of bias' tool, as  
430 well as the six additional criteria listed in Section 23.1.2 of the *Cochrane Handbook for*  
431 *Systematic Reviews of Interventions* that relate specifically to c-RCTs.<sup>34</sup> For randomised  
432 cross-over trials, we will use the Cochrane 'Risk of bias' tool, as well as the additional criteria  
433 listed in Section 23.2.3 of the *Cochrane Handbook for Systematic Reviews of Interventions*  
434 that relate specifically to randomised cross-over trials. For non-randomised controlled  
435 studies, we will use the Cochrane Effective Practice and Organisation of Care (EPOC) 'Risk  
436 of bias' tool. Biases will be classified as 'low', 'high' or 'unclear' and summarised in graphs.  
437 For observational studies, we will use the Cochrane Risk Of Bias In Non-randomised  
438 Studies - of Interventions (ROBINS-I) tool.<sup>35</sup> We will assess risk of bias through a hierarchy  
439 of domains, starting with 'critical', then 'serious', 'moderate', and 'low'. If any domain reaches  
440 critical risk of bias we will not continue with the assessment. We will make a risk of bias  
441 assessment for each outcome. If risk of bias is critical it will be excluded from the review.  
442 Highly relevant studies with a critical risk of bias may be included in a separate annex.

443

444

#### 445 **Measures of treatment effect**

446 We will compare intervention and control data using (preferably) risk ratios or odds ratios if  
447 the outcome is dichotomous. For continuous data, we will present the mean difference  
448 (when studies use the same outcome measurement scale, and SMD when studies use  
449 different outcome measurement scale); and for count/rate data, we will use rate ratios. We  
450 will use adjusted measures of effect to summarise treatment effects from non-randomised  
451 studies. We will present all results with their associated 95% CIs. We will report any  
452 accounts that signal adverse effects.

453

454

## 455 **Unit of analysis issues**

456 For c-RCTs, or non-randomised cluster trials, we will extract adjusted measures of effect  
457 where possible. If the study authors did not perform any adjustment for clustering, we will  
458 adjust the raw data ourselves using an ICC value. If an ICC is not reported, we will estimate  
459 this, with reference to similar studies, if possible. We will not present results from c-RCTs  
460 that are not adjusted for clustering. If we estimate the ICC, we will perform sensitivity  
461 analyses to investigate the robustness of our analyses. If we identify studies for inclusion  
462 that have multiple intervention arms, we will include data from these studies by either  
463 combining treatment arms, or by splitting the control group so that we only include these  
464 participants in the meta-analysis once. We will consider the level at which randomization  
465 occurred, such as cross-over trials, c-RCTs, and multiple observations for the same  
466 outcome. For randomised cross-over trials, where neither carry-over nor period effects are  
467 identified as problematic, we will use a paired t-test for the analysis of continuous data from  
468 two-period, two-armed cross-over trials.

469

## 470 **Dealing with missing data**

471 In case of missing data, we will apply available-case analysis and will include data on known  
472 results, as well as 'non-adherent' participants, excluded from the primary study authors'  
473 analysis, but for whom data are available.<sup>36</sup> 'Non-adherent' participant data may be included  
474 in "intention-to-treat" or "as-treated" analyses, as appropriate.<sup>36</sup> The denominator will vary  
475 according to the total number of participants who had data recorded for the specific outcome  
476 as well as the total number of excluded participants included per analysis type. For  
477 outcomes with no missing data, we plan to perform analyses on an "intention-to-treat" basis.  
478 We will include all participants randomised to each group in the analyses and will analyse  
479 participants in the group to which they were randomised. If further data are needed,  
480 respective authors, companies or organisations will be contacted to obtain missing data.

481

## 482 **Assessment of heterogeneity**

483

484 Heterogeneity will be assessed by visually examining the overlap of study CIs, applying Chi<sup>2</sup>  
485 and I<sup>2</sup> statistics. A Chi<sup>2</sup> test result with P value < 0.1 will indicate significant heterogeneity.  
486 Interpretation of I<sup>2</sup> will follow the classification: 30% to 60%: may represent moderate  
487 heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable  
488 heterogeneity. If we observe substantial heterogeneity we will perform further subgroup  
489 analysis. If appropriate we will explore clinical and methodological heterogeneity through  
490 consideration of the trial populations, methods, and interventions and by visualization of trial  
491 results.

492

## 493 **Assessment of reporting biases**

494 We will construct a funnel plot to assess reporting biases when performing an analysis of 10  
495 or more studies. We will explore reasons for funnel plot asymmetry, including true  
496 heterogeneity of the effect with respect to trial size, poor methodological design (and hence  
497 bias of small trials), and publication bias, and will interpret results accordingly.

498

## 499 **Data synthesis**

500 We will analyse data using Review Manager 5.<sup>37</sup> We will use fixed-effect meta-analysis to  
501 combine data if heterogeneity is absent. If considerable heterogeneity is present, we will  
502 combine data using random-effects meta-analysis and report an average treatment effect.

503 We will decide whether to use fixed-effect or random-effects models based on the  
504 consideration of clinical and methodological heterogeneity between trials.

505

### 506 **Certainty of the evidence**

507 We will assess the certainty of evidence using the GRADE approach.<sup>38</sup> Evidence will start as  
508 high-certainty. However, if there is bias due to confounding, missing data or selection of the  
509 report result, outcomes will be marked as moderate, high or unclear risk of bias and the  
510 evidence will be rated down accordingly to low-certainty evidence.

511 For c-RCTs, we will rate each important outcome as described by.<sup>39</sup> c-RCTs start as high  
512 quality evidence but can be downgraded if there are valid reasons within the following five  
513 categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias. Non-  
514 randomized studies can also be upgraded if there is a large effect, and if all plausible  
515 residual confounding would reduce a demonstrated effect or would suggest a spurious effect  
516 if no effect was observed.<sup>39</sup> We will summarise our findings in a 'Summary of findings' table.

517 We will summarise qualitative findings on consumer views e.g. user acceptability  
518 narratively. If there are a sufficient number of included studies, two review authors will  
519 independently code the studies, and use thematic synthesis to identify themes and  
520 subthemes.

521

### 522 **Subgroup analysis and investigation of heterogeneity**

523 We will stratify the analysis by study design, phase of humanitarian emergency (acute/post-  
524 acute, protracted and recovery/post-conflict phases) and primary mode of intervention  
525 action. Where substantial heterogeneity exists, we plan to perform the following subgroup  
526 analysis:

527

- 528 • Intervention coverage (appropriate levels to be determined with respect to the primary  
529 mode of action of each intervention, e.g. community-wide mass effect vs. personal  
530 protection).
- 531 • Participants (<5 years, pregnant women, adult, mixed age groups).
- 532 • Geographical region.
- 533 • Malaria vector species behaviour.
- 534 • Malaria transmission dynamics/seasonality.

535

536

### 537 **Sensitivity analysis**

538 We will perform sensitivity analysis on the primary outcome, to observe the effect of  
539 excluding trials at high risk of bias (for incomplete outcome data). If the ICC value is  
540 estimated, we will undertake sensitivity analyses to investigate the impact of varying the ICC  
541 value on meta-analysis results.

542

## 543 **ETHICS AND DISSEMINATION**

544 This systematic review and meta-analysis will consist of secondary analyses of existing  
545 anonymous data and meets the criteria for waiver of ethics review by the London School of  
546 Hygiene and Tropical Medicine. As this research is based on previously published data,  
547 there will be no patient and public involvement in the design, interpretation or dissemination

548 of study findings. This study protocol was drafted according to the Preferred Reporting Items  
549 for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) checklist.<sup>40</sup> Any  
550 amendments to this protocol will be documented and published alongside the results of the  
551 systematic review and meta-analysis. Study findings will be disseminated via open-access  
552 publications in peer-reviewed journals, presentations to stakeholders and relevant national  
553 and international policy makers and will contribute to the latest WHO guidelines for malaria  
554 control during humanitarian emergencies.

555

#### 556 **Authors' contributions**

557 LAM, JFA, BP and MR wrote the full text of the protocol. All review authors read and  
558 approved the final protocol draft.

559

#### 560 **Funding statement**

561 This work was supported by the World Health Organization Global Malaria Programme  
562 (WHO-GMP). LAM, JFA and MR are supported by the DFID/MRC/NIHR/Wellcome Trust  
563 Joint Global Health Trials Scheme. LAM and MR are also supported by UNITAID/Global  
564 Fund and DFID-RPC. BP is supported by the LSHTM-Nagasaki University Joint PhD  
565 Programme for Global Health. We are very grateful to Jane Falconer, Information Specialist,  
566 at the London School of Hygiene and Tropical Medicine, for help with the literature search  
567 strategy, and to Drs. Jan Kolaczinski, Jennifer Stevenson and Elie Akl (WHO-GMP) and Drs.  
568 Natacha Protopopoff and Natasha Howard (LSHTM) for valuable protocol suggestions. The  
569 funder of the study had no role in study design, data collection, data analysis, data  
570 interpretation, or writing of the report. The corresponding author had full access to all the  
571 data in the study and had final responsibility for the decision to submit for publication.

572

#### 573 **Competing interests statement.**

574 The authors declare no competing interests.

575

#### 576 **References**

577

- 578 1. World Health Organization 2019. World Malaria Report. Geneva, Switzerland: World  
579 Health Organization 2019.
- 580 2. Anderson J, Doocy S, Haskew C, *et al.* The burden of malaria in post-emergency  
581 refugee sites: a retrospective study. *Confl Health* 2011;5:17.
- 582 3. World Health Organization 2013. Malaria control in humanitarian emergencies: an  
583 inter-agency field handbook. Second edition Geneva: 2013.
- 584 4. The UN refugee Agency (UNHCR), 2020. Figures at a glance. Accessible from:  
585 <https://www.unhcr.org/uk/figures-at-a-glance.html> Accessed September 5<sup>th</sup> 2020.
- 586 5. The Malaria Atlas Project (MAP), 2020. Interactive map. Accessible from:  
587 <https://malariaatlas.org/> Accessed September 5<sup>th</sup> 2020.
- 588 6. Spencer S, Grant AD, Piola P, *et al.* Malaria in camps for internally-displaced  
589 persons in Uganda: evaluation of an insecticide-treated bednet distribution  
590 programme. *Trans R Soc Trop Med Hyg* 2004;98(12):719-27.
- 591 7. Richards AK, Banek K, Mullany LC, *et al.* Cross-border malaria control for internally  
592 displaced persons: observational results from a pilot programme in Eastern  
593 Burma/Myanmar. *Trop Med Int Health* 2009;14(5):512-21.

- 594 8. Smithuis FM, Kyaw MK, Phe UO, *et al.* The effect of insecticide-treated bed nets on  
595 the incidence and prevalence of malaria in children in an area of unstable seasonal  
596 transmission in western Myanmar. *Malaria J* 2013;12:363.
- 597 9. Charlwood JD, Qassim M, Elnsur EI, *et al.* The impact of indoor residual spraying  
598 with malathion on malaria in refugee camps in eastern Sudan. *Acta Trop*  
599 2001;80(1):1-8.
- 600 10. Rowland M, Nosten F. Malaria epidemiology and control in refugee camps and  
601 complex emergencies. *Ann Trop Med Parasit* 2001;95(8):741-54.
- 602 11. Rowland, M, Hewitt S, Durrani N, *et al.* Sustainability of pyrethroid-impregnated  
603 bednets for malaria control in Afghan communities. *Bull World Health Organ*  
604 1997;75(1):23-29.
- 605 12. World Health Organization 2012. Global plan for insecticide resistance management  
606 in malaria vectors. Geneva, Switzerland: World Health Organization 2012.
- 607 13. Bouma MJ, Parvez SD, Nesbit R, *et al.* Malaria control using permethrin applied to  
608 tents of nomadic Afghan refugees in northern Pakistan. *Bull World Health Organ*  
609 1996;74(4):413-21.
- 610 14. Graham K, Mohammad N, Rehman H, *et al.* Insecticide-treated plastic tarpaulins for  
611 control of malaria vectors in refugee camps. *Med Vet Entomol* 2002;16:404-08.
- 612 15. Graham K, Rehman H, Ahmad M, *et al.* Tents pre-treated with insecticide for malaria  
613 control in refugee camps: an entomological evaluation. *Malaria J* 2004;3:25.
- 614 16. Burns M, Rowland M, N'Guessan R, *et al.* Insecticide-treated plastic sheeting for  
615 emergency malaria prevention and shelter among displaced populations: an  
616 observational cohort study in a refugee setting in Sierra Leone. *Am J Trop Med Hyg*  
617 2012;87(2):242-50.
- 618 17. Graham K, Mohammad N, Rehman H, *et al.* Comparison of three pyrethroid  
619 treatments of top-sheets for malaria control in emergencies: entomological and user  
620 acceptance studies in an Afghan refugee camp in Pakistan. *Med Vet Entomol*  
621 2002;16:199-206.
- 622 18. Rowland M, Durrani N, Hewitt S, *et al.* Permethrin-treated chaddars and top-sheets:  
623 appropriate technology for protection against malaria in Afghanistan and other  
624 complex emergencies. *Trans R Soc Trop Med Hyg* 1999;93(5):465-72.
- 625 19. Macintyre K, Sosler S, Letipila F, *et al.* A new tool for malaria prevention?: results of  
626 a trial of permethrin-impregnated bedsheets (*shukas*) in an area of unstable  
627 transmission. *Int J Epidemiol* 2002;32:157-60.
- 628 20. Kimani EW, Vulule JM, Kuria IW, *et al.* Use of insecticide-treated clothes for personal  
629 protection against malaria: a community trial. *Malaria J* 2006;5:63.
- 630 21. Sochantha T, Van Bortel W, Savonnaroth S, *et al.* Personal protection by long-lasting  
631 insecticidal hammocks against the bites of forest malaria vectors. *Trop Med Int*  
632 *Health* 2010;15(3):336-41.
- 633 22. Sharma SK, Upadhyay AK, Haque MA, *et al.* Field evaluation of ZeroFly--an  
634 insecticide incorporated plastic sheeting against malaria vectors and its impact on  
635 malaria transmission in tribal areas of northern Orissa. *Indian J Med Res*  
636 2009;130(4):458-66.
- 637 23. Messenger LA, Miller NP, Adeogun AO, *et al.* The development of insecticide-treated  
638 durable wall lining for malaria control: insights from rural and urban populations in  
639 Angola and Nigeria. *Malaria J* 2012;11:332.
- 640 24. Kitau J, Oxborough R, Kaye A, *et al.* Laboratory and experimental hut evaluation of a  
641 long-lasting insecticide treated blanket for protection against mosquitoes. *Parasit*  
642 *Vectors* 2014;7:129.
- 643 25. Reyburn H, Ashford R, Mohsen M, *et al.* A randomised controlled trial of insecticide-  
644 treated bednets and chaddars or top-sheets, and residual spraying of interior rooms  
645 for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. *Trans R Soc*  
646 *Trop Med Hyg* 2000;94:361-366.

- 647 26. Rowland M, Downey G, Rab A, *et al.* DEET mosquito repellent provides personal  
648 protection against malaria: a household randomized trial in an Afghan refugee camp  
649 in Pakistan. *Trop Med Int Health* 2004;9(3):335-42.
- 650 27. Rowland M, Freeman T, Downey G, *et al.* DEET mosquito repellent sold through  
651 social marketing provides personal protection against malaria in an area of all-night  
652 mosquito biting and partial coverage of insecticide-treated nets: a case-control study  
653 of effectiveness. *Trop Med Int Health* 2004;9(3):343-50.
- 654 28. Rowland M, Durrani N, Kenward M, *et al.* Control of malaria in Pakistan by applying  
655 deltamethrin insecticide to cattle: a community-randomised trial. *Lancet*  
656 2001;357(9271):1837-41.
- 657 29. Majambere S, Pinder M, Fillinger U, *et al.* Is mosquito larval source management  
658 appropriate for reducing malaria in areas of extensive flooding in The Gambia? A  
659 cross-over intervention trial. *Am J Trop Med Hyg* 2012;82(2):176-84.
- 660 30. World Health Organization 2019. Global Malaria Programme. Guidelines for Malaria  
661 Vector Control.
- 662 31. World Health Organization 2020. List of WHO prequalified vector control products  
663 [www.who.int/pq-vector-control/prequalified-](http://www.who.int/pq-vector-control/prequalified-lists/PrequalifiedProducts27January2020.pdf?ua=1)  
664 [lists/PrequalifiedProducts27January2020.pdf?ua=1](http://www.who.int/pq-vector-control/prequalified-lists/PrequalifiedProducts27January2020.pdf?ua=1). Accessed June 17<sup>th</sup> 2020.
- 665 32. Maia MF, Kliner M, Richardson M, *et al.* Mosquito repellents for malaria prevention.  
666 *Cochrane Database Syst Rev* 2018;2.
- 667 33. Furnival-Adams J, Olanga EA, Napier M, *et al.* Housing interventions for preventing  
668 malaria. *Cochrane Database Syst Rev* 2019;8.
- 669 34. Higgins JPT, Thomas J, Chandler J, *et al.* eds. *Cochrane Handbook for Systematic*  
670 *Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available  
671 from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- 672 35. Sterne J, Hernán MA, Reeves Barnaby C, *et al.* ROBINS-I: a tool for assessing risk  
673 of bias in non-randomised studies of interventions; *BMJ* 2016; 355; i4919.
- 674 36. Akl EA, Johnston BC, Alonso-Coello P, *et al.* Addressing dichotomous data for  
675 participants excluded from trial analysis: a guide for systematic reviewers. *PLoS One*  
676 2013;8(2):e57132.
- 677 37. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan  
678 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration,  
679 2014.
- 680 38. Guyatt GH, Oxman AD, Schunemann HJ, *et al.* GRADE guidelines: a new series of  
681 articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* 2011;64(4):380-2.
- 682 39. Balshem H, Helfand M, Schunemann HJ, *et al.* GRADE guidelines: 3. Rating the  
683 quality of evidence. *J Clin Epidemiol* 2011;64(4):401-6.
- 684 40. Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic  
685 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.  
686 *BMJ* 2015;349:g7647.
- 687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701

702 **Table 1.** Key factors influencing choice of vector control intervention(s) during humanitarian  
703 emergencies.  
704

Key Factors	Sub-Factors
Malaria epidemiology	Level of endemicity; local transmission dynamics and stability; circulating <i>Plasmodium</i> species and proportions of co-infection; level of drug resistance; asymptomatic infections
Human population composition and behaviour	Population origin and size; displacement dynamics and mobility; level of prior malaria exposure; proportion of vulnerable individuals (for example, pregnant women, children and the elderly); age and sex distributions; sleeping location and night-time behaviour; knowledge of malaria; education; healthcare and treatment seeking behaviour; prevalence of comorbidities (for example, malnutrition, anaemia, HIV); gender mobility and work practices
Vector species distribution and behaviour	Local vector species composition; vector seasonality; host preference (anthropophilic/zoophilic); feeding time and location (early/late biting and indoor/outdoor biting); resting location (indoor/outdoor resting); level of insecticide resistance; flight range; breeding site preference
Emergency setting and infrastructure	Type of shelter or housing available (for example, <i>ad-hoc</i> refuse materials, plastic sheeting, tents, more permanent housing); road access and condition; camp or community organisation and layout; prior and present vector control interventions or programmes; timing of rainy seasons; potential to impact other vector-borne diseases (such as in areas of sympatric leishmaniasis) and nuisance insects (for example, lice, fleas, ticks, biting flies, bed bugs)

705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715

716 **Table 2.** Types of intervention to be included in this review.

<b>Intervention Category</b>	<b>Examples of Intervention</b>	<b>Control*</b>
Insecticide-treated temporary housing materials	Plastic sheeting; tarpaulins; tents	Untreated temporary housing material
Insecticide-treated bedding materials	Sheets; blankets; chaddars; top sheets	Untreated bedding material
Insecticide-treated wall linings	Plastic woven or non-woven mesh material used to cover housing structure/shelters	Untreated wall lining
Insecticide-treated clothing	Military uniforms; occupational clothing	Untreated clothing
Insecticide-treated curtains	Netted curtain or window material	Untreated curtains
Insecticide treatment of livestock	Cattle dipping; use of endectocides	No cattle dipping/endectocide use
Personal repellents	Spatial repellents; topical repellents; insecticidal soaps	No spatial repellent
Bed nets	Long-lasting insecticidal nets (LLINs); insecticide-treated nets (ITNs); untreated nets (UTNs)	Untreated bed nets (when compared to insecticidal counterparts)
Indoor residual spraying (IRS)	Chemical treatment of housing structure/shelters	No chemical treatment of housing structures/shelters
Larval source management (LSM)	Chemical or biological treatment of breeding sites; habitat modification or manipulation	No insecticidal or mechanical control

717 \*Studies where the control group comprises no other insecticidal malaria vector control  
 718 intervention will also be considered. Use of other vector control tools (in addition to the  
 719 intervention under evaluation) must be balanced between study arms.  
 720

721  
 722  
 723





# Phases of Humanitarian Emergencies

